

THRU E-MAIL

April 1, 2024

The Secretary
BSE Ltd.
Phiroze Jeejeebhoy Towers
27th Floor, Dalal Street
Mumbai 400 023
corp.relations@bseindia.com

The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Flr, Plot # C/1
G Block, Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051
takeover@nse.co.in

Dear Sir,


Re: Declaration under Regulation 31 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 - Krebs Biochemicals & Industries Ltd.-
(Scrip code: BSE: 524518 and NSE: KREBSBIO)

Pursuant to Regulation 31 (4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we as promoters hereby declare that we have not made any encumbrance, directly or indirectly, on shares held by us in Krebs Biochemicals & Industries Ltd.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully
For Ipca Laboratories Limited



Harish Kamath
Corporate Counsel & Company Secretary

Cc: 1. Krebs Biochemicals and Industries Limited
Kothapalli (V), Kasimkota (M)
Anakapalli, Vishakapatnam (D)
Andhra Pradesh – 531 031
com_sec@krebsbiochem.com

2. Audit Committee of Board of Directors of Krebs Biochemical & Industries Ltd..

Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837